BioSpace News Archive

Kernel, an innovator in non-invasive neuroimaging technology, announces the first patient has been measured in an observational study of depression treatments using Kernel’s revolutionary Flow2 neuroimaging technology.

Biofrontera Inc. announced the appointment of Samantha Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023.

Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, at 4:15 p.m. Eastern Time.

Neurocrine Biosciences, Inc. presented findings from a data analysis of KINECT®-4 demonstrating a comparable pattern of improvement over time of clinician-rated tardive dyskinesia severity and awareness/distress as measured by the Abnormal Involuntary Movement Scale and patient-reported TD impact as measured by the Trajectories of Tardive Dyskinesia Impact Scale.

Evotec SE announced its financial results and corporate updates for the first half-year of 2023.

Halozyme Therapeutics, Inc. announced the approval of Roche’s Tecentriq® SC, using Halozyme’s ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain.

Theravance Biopharma, Inc. will participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12 at 9:30 am ET and will be hosting in-person meetings with the investment community at the conference.

Haemonetics Corporation has announced that for the first time, patients have been treated with the company`s VASCADE MVP® Venous Vascular Closure system in Germany.

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 7:30 a.m. EST.